Results showed a significant decrease in total cholesterol (p = 0.016), triglyceride (p = 0.049), hepatic steatosis (p = 0.041), and C-reactive protein levels (p = 0.029) versus placebo, probably due to an inhibition of the NF-kB pathway. This evidence concerns the gene NFKB1 and fatty liver disease.